Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater
Prospective Study Of Ophthalmologic Function In Patients Receiving Linezolid For Six Weeks Or Greater
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Genova, Italy, 16132
- Università di Genova
-
Genova, Italy, 16132
- Azienda Ospedaliera Universitaria di San Martino
-
Genova, Italy, 16132
- Ospedale San Martino, Clinica Malattie Infettive
-
Udine, Italy, 33100
- Clinica Malattie Infettive, Azienda Ospedaliero Universitaria Santa Maria della Misericordia
-
-
-
-
-
Stockholm, Sweden, 141 86
- Infektionskliniken 1-73, Karolinska Universitetssjukhuset Huddinge
-
-
-
-
Arkansas
-
Jonesboro, Arkansas, United States, 72401
- St. Bernards Research Center
-
-
Florida
-
West Palm Beach, Florida, United States, 33401
- Triple O Research Institute, PA
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Clinic Foundation
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Health System
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota, Department of Medicine/Division of Infectious Diseases
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19102
- Drexel University College of Medicine, Partnership Comprehensive Care Practice
-
Pittsburgh, Pennsylvania, United States, 15206
- Associates in Infectious Disease and Tropical Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects who are 18 years of age or older.
- Subjects in Treated Group:
- Subjects must have received linezolid 600 mg BID for six weeks or greater and be currently on drug (or have received linezolid within 7 days of baseline evaluation).
- Subjects who have current signs or symptoms compatible with linezolid toxicity (i.e. optic or peripheral neuropathy) may be enrolled in the study if they are on linezolid at time of baseline evaluation (or have received linezolid within 7 days of baseline evaluation).
- Linezolid may be discontinued at any time at the primary physician's discretion and remain on the study.
- Women of childbearing potential must use adequate contraception
- Subjects in Control Group:
- Subjects will have a diagnosis similar to patients in the treated group and similar important co-morbidities and epidemiologic factors if possible.
Exclusion Criteria:
- Subject in Treated Group:
- Subjects with a known presence of optic or peripheral nerve damage due to another illness, condition or medication.
- Subjects with a pre-existing or a diagnosis at time of screening visit of an ophthalmologic condition that would adversely affect the study testing protocol (e.g. dense cataracts, macular degeneration, retinitis pigmentosa).
- Subjects who are currently receiving or anticipated to receive another medication, antibiotic or other, that has known potential to produce ocular or neurologic toxicity indistinguishable from that caused by linezolid or lactic acidosis.
- Subjects with a history of significant exposure, in the opinion of the investigator and with prior discussion with the medical monitor, to medications known to produce optic or peripheral neuropathy.
- Subjects with an active communicable disease (i.e., tuberculosis assessed as currently communicable) and subjects on active treatment for tuberculosis or other mycobacterial disease that include drugs that have known potential to produce ocular or neurologic toxicity.
- Subjects with severe liver disease or abnormal liver function test.
- Subjects in Control Group:
- Subjects must not currently be taking linezolid or have received it for more than 7 days at any time.
- Subjects with a known presence of optic or peripheral nerve damage due to another illness, condition or medication.
- Subjects with a pre-existing or a diagnosis at the screening visit of an ophthalmologic condition that would adversely affect the study testing protocol (e.g. dense cataracts, macular degeneration, retinitis pigmentosa).
- Subjects who are currently receiving another medication, antibiotic or other, that has known potential to produce ocular or neurologic toxicity indistinguishable from that caused by linezolid or lactic acidosis.
- Subjects with a history of significant exposure, in the opinion of the investigator and with prior discussion with the medical monitor, to medications known to produce optic or peripheral neuropathy.
- Subjects with an active communicable disease (i.e., tuberculosis assessed as currently communicable) and subjects on active treatment for tuberculosis or other mycobacterial disease that include drugs that have known potential to produce ocular or neurologic toxicity.
Study Plan
How is the study designed?
Design Details
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Linezolid
Subjects have received at least 6 weeks of linezolid therapy (600 mg BID).
Continued duration of linezolid treatment is based on treating physician's benefit/risk assessment.
A matching control who did not receive linezolid will be selected for each linezolid treated subject.
|
Observation and testing in patients for whom their treating physician has determined linezolid is an appropriate therapy.
Eye tests performed for subjects who have received linezolid for at least 6 weeks and matching controls who have received other antibiotics for similar types of infections.
|
|
Active Comparator: Matched control
Control subjects individually matched to linezolid subjects (on age, gender and type of infection) who received at least 6 weeks of antibiotics other than linezolid.
Control group assessed only at baseline visit to assess presence of background abnormalities in the study test panel.
|
Matched controls received an antibiotic other than linezolid for at least 6 weeks prior to baseline visit.
The control group had only a baseline visit and there were no post baseline study visits.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of Participants With an Adverse Event
Time Frame: Through and including 28 calendar days after the last administration of the investigational product
|
Through and including 28 calendar days after the last administration of the investigational product
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants by Clinical Outcome of Infection at End of Study
Time Frame: At End of Study visit
|
Clinical response was evaluated at the End of Study visit (30 days after last dose) as Cure, Improvement, Failure, Unknown or Other.
Clinical response was based primarily on the global assessment of the clinical presentation of the subject made by the investigator at that evaluation timepoint.
The clinical response classifications were defined as follows.
Cure: Resolution of the clinical signs and symptoms of infection, when compared to Baseline.
No additional antimicrobial treatment is required for the disease under study.
Improvement: Improvement in 2 or more, but not all, of the clinical signs and symptoms of infection, when compared with Baseline.
No additional antimicrobial treatment is required for the disease under study.
Failure: Persistence or progression of Baseline clinical signs and symptoms of infection, or development of new clinical findings consistent with active infection.
Unknown: Inability to assess clinical response.
|
At End of Study visit
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- A5951110
- 2006-002303-14 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.